mifepristone · Corcept Therap · NDA 202107
Korlym
Earliest generic entry, as listed
22 Aug 2038
Blocked by patent: US 10231983, US 10314850, US 10780097. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 18 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10231983 | use U-1643 · sets the listed date | 22 Aug 2038 |
| US 10314850 | use U-1643 · sets the listed date | 22 Aug 2038 |
| US 10780097 | use U-1643 · sets the listed date | 22 Aug 2038 |
| US 10195214 | use U-1643 | 19 Jun 2037 |
| US 10842800 | use U-1643 | 19 Jun 2037 |
| US 11969435 | use U-1643 | 19 Jun 2037 |
| US 12097210 | use U-1643 | 19 Jun 2037 |
| US 10151763 | use U-1643 | 18 Jan 2037 |
| US 9829495 | use U-1643 | 15 Aug 2036 |
| US 10006924 | use U-1643 | 12 Aug 2036 |
| US 10495650 | use U-1643 | 12 Aug 2036 |
| US 10166242 | use U-1643 | 20 Apr 2036 |
| US 10166243 | use U-1643 | 20 Apr 2036 |
| US 10660904 | use U-1643 | 20 Apr 2036 |
| US 9943526 | use U-1643 | 20 Apr 2036 |
| US 10500216 | use U-1643 | 5 Mar 2033 |
| US 10842801 | use U-1643 | 15 Nov 2032 |
| US 8921348 | use U-1643 | 27 Aug 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 202107 · 001 · RLD | tablet, oral | 300MG | 22 Aug 2038 |